ReviewCells2026
Aberrant Transcription-Factor Expression and Regulatory microRNAs in Metastatic Breast Cancer.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic breast cancer is driven by reversible cell-state programs shaped by transcription factors (TFs) and microRNAs (miRNAs). Dysregulated TFs integrate oncogenic signaling, hypoxia, inflammation, lineage identity, mechanical cues, and chromatin state, whereas miRNAs buffer or reinforce these programs through post-transcriptional repression. Their reciprocal interactions form dynamic regulatory circuits controlling epithelial-mesenchymal plasticity, stem-like behavior, invasion, dissemination, dormancy, organ-specific colonization, immune escape, and treatment resistance. This narrative review examines major TF-miRNA modules implicated in breast cancer metastasis, including ZEB1/2-miR-200/miR-205, TWIST1-miR-10b, MYC-miR-9, FRA-1-miR-34, FOXM1-miR-671-5p, HIF-1α-miR-18a, mutant p53/HIF-1α-miR-30d, STAT3-miR-21/miR-34a, and the context-dependent FOXP3-miR-200c/miR-141 network. Evidence from experimental models, paired primary-metastatic tissues, circulating tumor cells, extracellular vesicles, and plasma cohorts is integrated with emphasis on disease stage, molecular subtype, and biological compartment. Tissue and circulating miRNA signals are not interchangeable, and FOXP3-miR-200c relationships appear compartment- and model-dependent. Clinical translation remains limited by tumor heterogeneity, pre-analytical variability, incomplete cellular resolution, and limited causal validation. Prospective, subtype-stratified studies integrating spatial, single-cell, metastatic-tissue, and standardized liquid-biopsy analyses are required before TF-miRNA signatures can guide clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.